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Obesity is a multifactorial and complex condition that is characterized by abnormal and
excessive white adipose tissue accumulation, which can lead to the development of
metabolic diseases, such as type 2 diabetes mellitus, nonalcoholic fatty liver disease,
cardiovascular diseases, and several types of cancer. Obesity is characterized by
excessive adipose tissue accumulation and associated with alterations in immunity,
displaying a chronic low-grade inflammation profile. Adipose tissue is a dynamic and
complex endocrine organ composed not only by adipocytes, but several immunological
cells, which can secrete hormones, cytokines and many other factors capable of regulating
metabolic homeostasis and several critical biological pathways. Remarkably, adipose tissue is
a major source of circulating microRNAs (miRNAs), recently described as a novel form of
adipokines. Several adipose tissue–derived miRNAs are deeply associated with adipocytes
differentiation and have been identified with an essential role in obesity-associated
inflammation, insulin resistance, and tumor microenvironment. During obesity, adipose
tissue can completely change the profile of the secreted miRNAs, influencing circulating
miRNAs and impacting the development of different pathological conditions, such as obesity,
metabolic syndrome, and cancer. In this review, we discuss how miRNAs can act as
epigenetic regulators affecting adipogenesis, adipocyte differentiation, lipid metabolism,
browning of the white adipose tissue, glucose homeostasis, and insulin resistance,
impacting deeply obesity and metabolic diseases. Moreover, we characterize how miRNAs
can often act as oncogenic and tumor suppressor molecules, significantly modulating cancer
establishment and progression. Furthermore, we highlight in this manuscript how adipose
tissue–derived miRNAs can function as important new therapeutic targets.
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The worldwide statistics of overweight and obesity are considered a threat and contribute to a set of
risk factors that enhances the development of several other diseases, such as type 2 diabetes,
cardiovascular diseases, and cancer (1). Obesity is considered a low-grade chronic inflammation
disease, which can lead to increased insulin resistance, altered preadipocyte differentiation, pre-
existing adipocyte hypertrophy, macrophages infiltration and polarization, and the release of
inflammatory cytokines (2).n.org October 2020 | Volume 11 | Article 5638161
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homeostasis, with triglycerides accumulation and prominent
adipocyte hypertrophy, resulting in hypoxia, adipocyte cell death,
and free fatty acids released. There is also an intense inflammatory
profile in adipose tissue from obese people due to the excessive
macrophages and other immune cells infiltration to this tissue (3),
which also contribute to the adipocyte cell death and free fatty
acids release. Both adipocytes and immune cells are relevant
sources of cytokines and chemokines secretion in adipose tissue.
During obesity, the adipose tissue increases in mass and quantity,
with a significant change in its metabolic and immunological
profile, followed by adipocyte lytic cell death. This adipocyte
death triggers free fatty acids and several metabolites release,
thus pivoting the immune repertoire toward a type 1 (pro-
inflammatory) state and establishing a microenvironment that
supports oxidative stress, free radicals generation associated with
DNA damage and mutations. These parameters can directly
contribute to turning this microenvironment into a pro-
carcinogenic model. Moreover, an increased free fatty acids
release in adipose tissue during obesity can provide a direct
faster source of energy for cancer cells, also remodeling the
immune cell landscape and facilitating tumor establishment and
development (4, 5). In addition, several inflammatory genes
upregulation in immune cells can drive the inflammatory
response itself in adipose tissue, contributing to the insulin
resistance and glucose intolerance (6), critical factors associated
with metabolic syndrome. Therefore, those metabolic and
inflammatory changes in adipose tissue can disrupt physiological
homeostasis both within local tissues and systemically, impacting
directly the obesity development, as well as the initiation and
progression of cancer and metabolic syndrome, creating positive
feedback loops among them. Metabolic syndrome is defined as a
cluster of metabolic disorders components, including obesity,
cardiometabolic alterations, associated with other diseases such
as type 2 diabetes, hypertension, and dyslipidemia with
dysregulated levels of non-esterified fatty acids (NEFA) and
decreased levels of high-density lipoprotein (HDL) (7).
Metabolic syndrome leads to a higher secretion of inflammatory
mediators, such as leptin, tumor necrosis factor alpha (TNF-a),
monocyte chemoattractant protein-1 (MCP-1), resistin, and
interleukin 6 (IL-6) (8). This prevalent inflammatory profile
described in metabolic syndrome does not result from tissue
injury, infection, or an autoimmune response, but instead, a
meta-inflammation (9). Meta-inflammation is a chronic state of
inflammation characterized by dysregulation of proinflammatory
cytokines and chemokines, and mediated by macrophages (10).
Recent studies have highlighted the importance of adipose tissue
resident macrophages as a principal source for this inflammatory
signature supporting meta-inflammation and miRNAs are key
molecules in these signaling pathways (11).ADIPOSE TISSUE AND MACROPHAGES
Adipose tissue can be classified into white, brown, beige and pink
adipose tissues, which display different regulatory, morphologicalFrontiers in Endocrinology | www.frontiersin.org 2and functional characteristics of their adipocyte and immune cells
(12). White adipose tissue (WAT) acts as a reservoir for energy
storage and secretes paracrine factors that regulate other metabolic
tissues. WAT is significantly expanded during obesity triggering
several harmful effects, including inflammation, altered adipokines
secretion, fibrosis, hypoxia, and mitochondrial dysfunction (13).
Brown adipocytes precursors can transdifferentiate into white or
beige, as wells as precursors of white adipocytes can differentiate
into brown and beige (14). The brown adipose tissue (BAT) is
related to a higher thermogenic activity, supporting non-shivering
thermogenesis, and recently identified and characterized by
proteomics-based analysis, secreted factors from BAT, known as
batokines, targeting immune cells, regulating glucose homeostasis
and insulin sensitivity, angiogenesis, and neurite outgrowth (15,
16). Recent studies have shown the role of miRNA in adipocyte
development, metabolic functions, proliferation, and
differentiation (17). The beige adipose tissue is an intermediate
phenotype of WAT to BAT, which when stimulated by cold
exposure or b-3 adrenergic agonists may lead to increased BAT
markers expression, such as the uncoupling protein 1 (UCP-1),
PGC-1a, PGC-1b, CIDEA, PPARg, and PRDM16 (18). A forth
type of adipose tissue, is the pink adipose tissue mainly composed
by pink adipocytes (19, 20), which are milk-secreting alveolar cells
that can arise from transdifferentiation of white adipocytes during
pregnancy and lactation.
Macrophages can function as key sentinel orchestrators of the
immune activity in adipose tissues. Adipose tissue resident
macrophages have an important role mediating meta-
inflammation, secreting inflammatory mediators such as
chemokines, activating the recruitment of more immune cells
to the adipose tissues (21, 22). Among all immune cells within
the adipose tissue, macrophages contributed predominantly to
the activation of inflammatory pathways within adipose tissues
during the establishment of obesity and other metabolic
diseases (23).
The infiltration of macrophages in adipose tissue, surrounding
dead adipocytes can form the crown-like structures (CLSs), which
are directly related to increased tissue inflammation and release of
free fatty acids and other pro-inflammatory molecules. In obesity,
there is an exacerbated presence of CLS in WAT (24). It has been
described that CLS can promote the survival and proliferation of
breast cancer in patients with obesity, influencing the tumor
microenvironment (25).
The exposure of adipose tissue macrophages to different pro-
or anti-inflammatory cytokines can lead to two polarization
profiles, M1 (pro-inflammatory) and M2 (anti-inflammatory),
respectively (26). The M1 profile is induced by interferon gamma
(IFN-g), microbial products such as LPS, and tumor necrosis
factor alpha (TNFa). It is characterized by the release of
increased levels of reactive oxygen species, interleukins IL-12,
IL-10, and IL-23 (27). The M2 phenotype is triggered by
glucocorticoid hormones and interleukins IL-4, IL-13, IL-10,
and increased expression of arginase 1, also related to cell
growth and proliferation (28). Lumen and colleagues analyzed
white adipose tissue macrophages from lean and obese mice,
showing that the M1 macrophages were prevalent in adiposeOctober 2020 | Volume 11 | Article 563816
Heyn et al. miRNAs in Obesity and Cancertissue from obese mice. Moreover, in adipose tissue from lean
mice, macrophages mostly polarized to M2 profile and presented
a higher expression of anti-inflammatory proteins, such as
arginase (29).
Both adipocytes and macrophages within the adipose tissue can
secrete miRNAs, developing an important role between adipocytes
and macrophages communication, as well as impacting on
macrophages polarization and the inflammatory status of adipose
tissue, as summarized in Figure 1. The polarization of macrophages
to M1 or M2 phenotypes can be also regulated by miRNAs.
Upregulation of miRNA-181a, miR-155-5p, and miR-451 is
related to M1 polarization, contributing to the inflammatory
status of adipose tissue (30). Adipose tissue macrophages could
also regulate obesity-induced inflammation by downregulating
miR-30 in high fat diet-induced obese mice, promoting the
Notch1 signaling and M1 phenotype switch (31). Increased
release of miR-155 by adipose tissue macrophages in obese mice
is associated with insulin resistance and PPARg modulation (32).
Moreover, analysis from adipose tissue from knockout mice lacking
miRNA-181, showed an increased expression of genes associated
with M2macrophages polarization as Ym1, Realm, and Arg1, while
the genes related to pro-inflammatory M1macrophage polarization
were reduced (33). Therefore, miRNAs are key players in theFrontiers in Endocrinology | www.frontiersin.org 3adipocytes and immune cells crosstalk in adipose tissue,
contributing significantly to the inflammatory status of
this microenvironment.THE BIOGENESIS OF miRNAs
The miRNAs are small non-coding RNAs consisting of 19-23
nucleotides that regulate several biological processes mostly
through post-transcriptional gene silencing mechanism and
RNA interference. miRNAs suppress post-transcriptional
activity, acting on several genes and many of these non-coding
nucleotides are related to adipocyte development, lipolysis,
insulin sensitivity, glucose uptake (34), and multiple cytokines
release (35). It is known that hundreds of miRNAs can regulate
up to 30% to 80% of genes encoded in the human genome, which
each miRNA can target more than one hundred genes,
undertaking gene regulation (36) A single miRNA may have
multiple target sites in the 3’UTR region of a specific mRNA
(messenger RNA) (36). The biogenesis of the miRNA can be
distinguished into a canonical and non-canonical pathway.
The canonical transcriptional pathway begins with the RNA
polymerase II/III leading to a long primary miRNA transcript,FIGURE 1 | Adipose tissue–derived miRNAs modulate inflammation and tumor microenvironment. The adipose tissue produces and secretes several miRNAs that
dynamically regulate the tissue homeostasis. These miRNAs can be secreted by both adipose tissue and macrophages, playing a crucial role impacting on
inflammatory pathways, angiogenesis, cell growth, cell proliferation, and contributing to tumor development. The lean adipose tissue is characterized by an infiltrate of
M2 polarized macrophages and TCD4+ lymphocytes. The secretion of miR-223, suppressing PBX/Knotted 1 Homeobox 1 (Pknox1), is shown to inhibit the
activation of pro-inflammatory M1 macrophages, leading to an anti-inflammatory environment. The miR-145 exerts a tumor suppressor role, associated to the
inhibition of oncogenic transcriptional factor C-MYC. The transition from lean to obese adipose tissue is characterized by the adipocytes hypertrophy, an increase of
blood vessels and pro-inflammatory cell recruitment and polarizing as a common feature of obesity. Regarding the inflammatory recruitment, the infiltration of pro-
inflammatory macrophages around the dying adipocytes is strongly present, forming structures known as CLS (crown-like structures), associated with the secretion
of multiple inflammatory factors and considered an aggressiveness marker in breast cancer. The miR-21 is depicted being secreted by adipose tissue macrophages,
also known as an oncomiR or oncogenic, through PTEN silencing, thus leading to the activation of tumor growth and proliferation pathways. The miR-155
contributes to the activation of the inflammatory response. The miR-222 is associated with angiogenesis, one of the tumor development hallmarks. The oncogenic
miR-27a can lead to the inhibition of Forkhead box transcription factor O1 (FOXO1), an antitumoral multifunctional transcription factor, regulating genes linked to cell
cycle arrest and apoptosis.October 2020 | Volume 11 | Article 563816
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pri-miRNAs are transcribed and processed into pre-miRNAs by a
complex consisting of an RNA-binding protein called DGCR8
(DiGeorge Syndrome Critical Region 8) and a ribonuclease III,
Drosha, while DGCR8 recognizes the N6-methyladenylated GGAC
and other motifs in the pri-miRNA are recognized by DGCR8. The
DROSHA cleaves the duplex of pri-miRNA in the structure of the
hairpin, resulting in the pre-miRNA. The pre-miRNA is
transported into the cytoplasm by exportin 5 (XPO5)/RanGTP
and then processed by Dicer RNase III endonuclease (38). The
miRNA biogenesis and the impact of miRNAs on metabolic
syndrome, obesity and cancer are summarized in Figure 2. The
removal of the terminal loop leads to the mature miRNA duplex,
which in turn is incorporated into a multimeric complex called
RISC, including the Argonaut proteins as the main components, in
an ATP-dependent manner.
In the canonical pathway, miRNAs are generated by
transcriptional units of protein-coding, while in the non-canonical
pathway they are generated from non-protein-coding
transcriptional units. Another critical difference between these two
pathways is that in a canonical way the intronic miRNAs are
Drosha-dependent and then processed with protein-coding
transcripts in the nucleus. The pre-miRNA undergoes splicing
producing the mature mRNA which directs to protein synthesis.
In the non-canonical pathway, small introns of RNA, called
mirtrons, are not processed by Drosha (39).Frontiers in Endocrinology | www.frontiersin.org 4miRNAs show an essential role in gene expression, through
mRNA degradation, deadenylation, or inhibiting the protein
translational (40). Recent studies have shown that inhibition of
Drosha and Dicer enzymes, critical in miRNA biogenesis,
corroborated to the blockage of adipocytes differentiation and
adipogenesis. Adipocytes are the major site of exosomal miRNAs,
acting on cell to cell communication, as biomarkers in several
diseases, including type 2 diabetes and cancer (41). The Dicer
enzyme processes miRNA in the cytoplasm, a crucial stage of the
miRNA biogenesis. The silencing of Dicer enzyme in adipose
tissue, in a mice model, exhibited abnormal fat accumulation in
the interscapular region and intra-abdominal, whitening of brown
adipocytes, lipodystrophy, dyslipidemia, and insulin resistance
(42). Lipodystrophy, characterized by lipoatrophy, loss of adipose
tissue or abnormal distribution in specific regions anatomically, is
a clinical manifestation of metabolic syndrome, as well as
increased visceral fat accumulation and dyslipidemia (43).THE ROLE OF miRNAs IN WHITE AND
BROWN ADIPOSE TISSUE
Several works have shown the role of miRNAs in the development
of metabolic disease, glucose homeostasis, and progression of
obesity (44–47). miRNAs can exhibit a crucial impact on adipose
tissues (Table 1) and influence the phenotype and function of whiteFIGURE 2 | miRNAs processing and releasing by adipocytes and their influence on metabolic syndrome, obesity and cancer. Adipocytes are the main source of
circulating miRNAs in mice and human. The process of miRNA maturation begins in the nucleus with the gene transcription by RNA polymerase II or III in pri-miRNA.
Following the maturation process, the enzyme DROSHA and its Pasha cofactor leads to the pre-miRNA, which are exported to the cytosol by the Exportin-5 protein,
and further processed by Dicer enzyme, leading to the mature miRNA. It is taken into the RISC silencing complex and then become an active post-transcriptional
regulator. This may occur by cell free miRNA release, associated with apoptotic body, exosomes, or HDL. miRNAs can act influencing different types of cells.
Circulating miRNAs are able to control: (I) the expression of several genes related to adipogenesis, (II) the adipocyte differentiation and lipid metabolism impacting
obesity, (III) the expression of membrane proteins responsible for the glucose homeostasis and insulin resistance, (IV) the metabolic diseases development, and (V)
the cancer establishment and progression as oncomiR molecules.October 2020 | Volume 11 | Article 563816
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and inhibitors of brown adipogenesis and are crucial for adipose
tissue plasticity and dynamics of adipocytes differentiation (76, 77).
The absence of miRNAs can impact the differentiation of white
adipocyte into brown adipocyte dynamics and can be involved in
the recruitment and activation of thermogenic adipocytes (75).
There is a strong correlation between miRNAs and the regulation
of browning of the WAT.
Adipose tissue–specific DGCR8 knockout mice presented
enlarged, but pale interscapular brown fat with decreased
expression of characteristic genes of brown fat and intolerant
to cold exposure (78). miR-182 and miR-203 were identified as
key regulators of the brown adipocyte development (78). The
recruitment and activation of constitutive BAT in humans, as
well as the transdifferentiation of visceral and subcutaneous
WAT into brown adipocytes appear as a new strategy for
obesity treatment (79). BAT associated thermogenesis increases
caloric burning, contributing to accelerating weight loss. That
highlights the perspectives of these new targets to restore the
normality of energy homeostasis and to struggle the progression
of obesity by modulating the plasticity of adipose tissue, mainly
visceral WAT (80). Since miRNAs are deeply associated with
adipocytes differentiation and obesity, circulating miRNAs are
very attractive biomarkers and therapeutic tools for obesity
prevention and treatment (46).
The miRNA cluster miR-193b and miR-365 may display a
regulation of brown fat fate through myogenesis and adipogenesis.
Sun and colleagues compared the genome-wide miRNA profileFrontiers in Endocrinology | www.frontiersin.org 5expression of the epididymal WAT, skeletal muscle and
interscapular BAT. The WAT samples presented an upregulation
of miR-193b and miR-365 during adipogenesis, and a
downregulation of up to 30% in BAT of ob/ob mice (metabolic
impairment). The authors showed that miR-193b induced myoblasts
to differentiate into brown adipocytes, and demonstrated that miR-
193b and miR-365 365 can serve as essential regulators for brown fat
differentiation, in part by repressing myogenesis (48).
The miR-103 expression could be related to impaired insulin
sensitivity and glucose uptake, possibly an attractive
pharmacological target in obesity and diabetes, promoting cell
adipogenesis by targeting MEF2D and activating AKT/mTOR
signaling pathway (81). The miR-103/107 also trigger endoplasmic
reticulum (ER) stress-mediated apoptosis by targeting the Wnt3a/
b-catenin/ATF6 signaling pathway in preadipocytes impairing
adipogenesis (82). Overexpression of miR-103/107 was observed
in obese mice and resulted in augmented accumulation of
triglycerides and impaired regulation of adipogenic genes, while
silencing of miR-103/107, improved glucose homeostasis and
insulin sensitivity (51). Caveolin-1 could explain one of the
mechanisms discussed for negative regulation regarding insulin
sensitivity of miRNA-103. The miR-103 targets caveolin-1 and
diminishes the expression of insulin receptors in the caveolae-
enriched plasma membrane (51).
miRNAs also display a master role in brown adipogenesis of
white fat progenitor cells, as reported for miR-196 in WAT. This
miRNA suppresses the transcriptional factor HOXC8, avoiding
the repression of its target C/EBPb (CCAAT/enhancer bindingTABLE 1 | The dynamics of miRNAs functions in adipose tissue microenvironment.
miRNAs Tissue Species Highlights References
miRNA-193b/365 BAT and WAT Mouse Myogenesis and adipogenesis (48)
miRNA-196a sWAT Mouse/Human Brown adipogenesis (49)
miRNA-103 3T3-L1 Mouse Insulin signaling impairment (50, 51)
miRNA-133a and
miRNA-133b
BAT and sWAT Mouse Brown adipogenesis inhibition (52, 53)
miRNA-27 BAT and sWAT Mouse/Human White adipogenesis regulation; higher risk in gastric cancer (54, 55)
miRNA-26a and miRNA-
26b
sWAT Human Adipocyte differentiation; insulin signaling activation (56, 57)
miRNA-145 MSC Mouse Insulin stimulated AKT pathway inhibition and tumor suppressor in lung
adenocarcinoma
(58, 59)
miRNA-34a BAT and liver Mouse/Human Browning adipogenesis suppression; antitumoral role in breast cancer (60, 61)





Human Vascular Remodeling; epithelial-to mesenchymal transition activation in breast
cancer
(63, 64)
miRNA-125b White preadipocytes Human Reduction of mitochondrial biogenesis, higher risk in prostate cancer (65, 66)
miRNA-320 3T3-L1 Mouse Insulin sensitivity inhibition (67)
miRNA-33 Subcutaneous
Preadipocytes
Human Lipid homeostasis regulation (68)
miRNA-375 3T3-L1, hASCS,
pancreatic islets
Mouse/human Glucose homeostasis regulation (69)
miRNA-377 3T3-L1 Mouse Adipogenesis regulation and tumor suppressor through SIRT1 inhibition (70)
miRNA-21 ADSC Human Adipogenic differentiation and oncogenic through a mechanism dependent on
PTEN downregulation
(71, 72)
miRNA-155 Brown preadipocytes Mouse/Human Adipogenesis, hypoxia activation and, overexpression in lung cancer (73, 74)October 2020 | Volume 11 | AWAT, white adipose tissue; BAT, brown adipose tissue; PTEN, Phosphatase and tensin homolog; SIRT1, sirtuin 1; hASCs, human adipose tissue stem cells; MSC, adipose tissue–derived
mesenchymal stem cells; ADSC, adipose tissue–derived stem cells.rticle 563816
Heyn et al. miRNAs in Obesity and Cancerprotein b), considered a key regulator of BAT gene (49).
Moreover, cold stimulus and b-3 adrenergic activation in white
adipocytes can activate miR-196 in WAT from mice (49).
miR-133 is involved in BAT activation. miR-133 directly targets
and negatively regulates PRDM16. In addition, inhibition of miR-
133 can promote differentiation of precursors from BAT to mature
brown adipocytes and increased mitochondrial activity in response
to cold exposure (83). The upregulation of PRDM16 is linked to a
decrease of miR-133a expression and browning of WAT
enhancement (53), suggesting that pharmacological strategies to
inhibit miR-133 could be very prominent to promote browning of
the WAT. Likewise, miR-155 is enriched in BAT but efficiently
inhibits adipogenic differentiation and development of the
thermogenic program in brown adipocytes. Moreover, miR-155–
null mice exhibit enhanced BAT function, while overexpressing
miR-155 in mice induced a diminished browning markers
expression, such as UCP1, BAT mass reduction, and a total
impairment of BAT function (84).
miR-27 can negatively regulate brown and white adipogenesis
both inmice (55, 85, 86) and humans (87, 88). miR-27 is reported to
promote adipogenesis of WAT, targeting the 3’UTR region of
PPARg (Peroxisome Proliferator-Activated Receptor gamma) (17).
The cold exposure can downregulate miR-27 expression in murine
BAT and subcutaneous WAT (55). The miR-27 can also reduce the
expression of brown markers genes, such as PRDM16, PPARa,
CREB (Cyclic AMP Response Element Binding Protein), and
PGC1b (Peroxisome Proliferator-Activated Receptor Gamma Co-
activator 1 b). Moreover, the overexpression of miRNA-27 is also
related to a higher risk of gastric cancer, promoting a
transformation of cancer-associated fibroblasts (54).
miR-26a and miR-26b can trigger adipocytes differentiation,
both in human and mice studies. The overexpression of miR-26a
and miR-26b promote adipocyte differentiation of human
multipotent adipose derived-stem cells (56). miR-26b also
modulates insulin-stimulated AKT activation via inhibition of
its target gene, PTEN (Phosphatase and tensin homolog), and
significantly increases insulin sensitivity via the PTEN/PI3K/
AKT pathway (57). Moreover, overexpression of miR-26b
significantly increases the mRNA expression of the adipogenic
markers, PPARg, fatty acid synthase (FAS), CCAAT/enhancer-
binding protein alpha (C/EBPa), and lipoprotein lipase (89).
The miR-143, miR-145, and miR-130 also exert a role in
adipogenesis. The miR-130 inhibits PPARg expression (90). The
liver analysis from obese mice shows an increased expression of
miR-143 and miR-145, also an association of these miRNAs
expression and changes of insulin-stimulated AKT signaling
pathway. The knockout mice for miR-143 and miR-145 did
not develop obesity in insulin resistance conditions (58).
miRNAs are differentially expressed in white and brown
adipocytes and may be important in defining the common
precursor cell for myocytes and brown adipocytes and thus have
distinct roles in energy‐storing versus energy‐dissipating cells. The
miR-455 is related to browning of WAT induction, upregulating
UCP-1 expression. Adipose-specific miR-455 transgenic mice
exhibit brown fat characteristics in subcutaneous white fat, after
cold exposure. miR-455 boosts AMPKa1 (AMP-activated kinase)Frontiers in Endocrinology | www.frontiersin.org 6activation through HIF-1a (hypoxia inducible factor 1 a subunit)
inhibitor (62). The AMPKa1 contributes to brown adipogenic effect
and induces mitochondrial biogenesis (91). The classic myogenic
miR-1 and miR-206 are absent in murine white adipocytes and
expressed both in brown pre‐ and mature adipocytes, strengthening
the concept that brown adipocytes andmyocytes can share a similar
progenitor cell lineage that specifies energy‐dissipating cells (92).
A higher miR-34a expression was detected in obese mice (60)
and on serum analysis from patients with type 2 diabetes (93).
The miR-34 suppresses browning of WAT, directly affecting
adiposity, adipocyte differentiation, and metabolism. It targets
FGFR1 (Fibroblast Growth Factor Receptor 1) and SIRT 1
(sirtuin 1) (60). The suppression of SIRT1 (sirtuin) is related
to impaired transcriptional regulation of brown and beige
markers through deacetylation of PPARGC1-a (60, 61). The
lentiviral-mediated knockdown of miR-34a under a high-fat diet
have shown a different pattern of perirenal and gonadal WAT
depots distribution, and less ill metabolic effects (94).
Microarray analysis of human WAT has revealed distinct
miRNA expression that may be dysregulated in patients with
obesity and other comorbidities, such as type 2 diabetes mellitus
and heart diseases (95). Dysregulation of miR-20, miR-98, miR-
197, and miR-331 were common in patients with obesity and
type 2 diabetes mellitus (96). The molecular pattern of miRNAs
may be distinct in patients with morbid obesity, as seen in a
circulating genome-wide miRNA pattern from obese patients
before and after bariatric surgery. The results revealed a
differentiated profile of miRNA expression in cases of severe
obesity. Among these miRNAs the miR-142-3p, miR-140-5p,
miR-15a, miR-520c-3p, and miR-423-5p were identified as
potential new biomarkers of severe obesity (97).
The overall miRNA screening of white subcutaneous
adipocytes performed in obese patients and in lean patients
reported an overexpression of miR-143-3p and miR-652-3p in
obese patients when compared to lean patients, also detected a
higher chemokine CCL2 production and lipolysis from necrotic
adipocytes from obese WAT, demonstrating an inflammatory
response triggered by these miRNAs overexpression. The
expression of these miRNAs has been reported to increase
insulin-stimulated lipogenesis, affecting genes at transcriptional
and post-transcriptional levels of insulin signaling (98).
The dysregulation of miRNAs expression in white and BATs
can be a valuable target and biomarker in diseases associated
with adipose tissue dysfunction, such as metabolic syndrome and
cancer (99, 100).THE FUNCTION OF ADIPOSE TISSUE
miRNAs IN METABOLIC SYNDROME
Metabolic syndrome is a cluster of cardiometabolic risk factors
characterized with obesity, hyperglycemia, dyslipidemia,
hypertension, atherogenic, prothrombotic, and proinflammatory
states, NAFLD, often associated with a condition of insulin
resistance (101, 102). Adipose tissue miRNAs have direct impactOctober 2020 | Volume 11 | Article 563816
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acting as key mediators of metabolic syndrome features. miRNAs
can regulate multiple pathways including insulin signaling, meta-
inflammation, adipogenesis, lipid metabolism, and food
consumption (103). The miRNAs are strongly related to immune
response dysfunctions in metabolic syndrome, as in macrophages
polarization (104), adipogenesis regulators and mediators of the
fatty acids metabolism, also contributing to adipocyte hypertrophy
in obesity, hepatic steatosis, and lipid homeostasis disorders, insulin
signaling pathways, b-pancreatic cells mass, and endocrine
function (105).
The first evidence highlighting miRNAs role in metabolic
syndrome was described in the studies using Drosophila
adipocytes, demonstrating that miR-14 had a suppressive effect
on fat metabolism through the MAPK and p38 pathways in this
model (99). The screening of several miRNAs demonstrated
correlation between obesity and metabolic syndrome, specially
linked to insulin resistance and regulation of b-pancreatic cells.
The beta-pancreatic cell death can trigger pancreatic dysfunction
and promote type 2 diabetes. Studies have reported the
overexpression of the miR-200 family in pancreatic islets. The
analysis of diabetic mice showed a negative regulation of miR-
200 in anti-apoptosis pathways, thus favoring beta-pancreatic
cell death (106). The overexpression of miR-7 in beta cells from
mice showed an impairment of insulin granule exocytosis (107).
Meta-inflammation is a common feature of metabolic
syndrome, and miRNAs can actively regulate this process, by
altering macrophages phenotype and modulating the
inflammatory molecules secretion within the adipose tissue.
Studies reported the ablation of miR-223 in mice undergoing a
high-fat diet, resulted in increased M1 macrophages infiltration, as
well, higher pro-inflammatory cytokines secretion, such as IL-6, IL-
12, TNF-a, and IL-1b (108). This meta-inflammation is also closely
related to changes in the proliferative pathways, as seen for miR-21
dysfunction in obesity, affecting angiogenesis and cell growth (103).
These miRNAs-mediated alterations detected in metabolic
syndrome, such as exacerbated meta-inflammation, enhanced c
proliferative and a pro-angiogenic microenvironment in WAT,
could partially explain the higher predisposition to several types
of cancer observed in people with obesity.
ThemiRNAs dysfunction in obesity andmetabolic syndrome was
detected on the FXR/SHP signaling pathway. Fat metabolism and
cholesterol homeostasis are one of the axes that can be unbalanced in
metabolic syndrome. The miR-33 is related to cholesterol trafficking
in vitro and HDL synthesis also regulates cholesterol transport and
lipid homeostasis (68, 109). The FXR/SHP can inhibit miR-34a
expression (110). The Farnesoid X Receptor (FXR) is a nuclear
receptor, controlling the regulation of genes expression related to
fatty acids metabolism, cholesterol levels, through inhibition of
cytochrome P450 7A1, which is necessary for hepatic bile acids
synthesis. The effect of miR-34a inhibition leads to an upregulation of
SIRT1 and dysregulation of FXR/SHP pathway in diet- induced
obese mice (111). The miR-34a can also reduce the NAD+
(Nicotinamide Adenine Dinucleotide) and SIRT1 activity, targeting
NAMPT (Nicotinamide Phosphoribosyltransferase), a key enzyme
for NAD+ synthesis. The overexpression of miR-34a increasesFrontiers in Endocrinology | www.frontiersin.org 7mRNA degradation of NAMPT, resulting in decreased levels of
NAMPT/NAD+. The dysregulation on this pathway alters PGC-1a
(Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-
alpha), SREBP-1c (Sterol Regulatory Element-Binding Transcription
Factor 1), and NF-kB, enhancing obesity. The antagonism of miR-
34a reduces hepatic steatosis, glucose intolerance, and inflammation.
The inhibition of miR-34a represents a potential therapeutic target
against obesity and metabolic syndrome (112).
The miR-30c is related to hMADS (humanmultipotent adipose-
derived stem cells) and promotes adipogenesis and accumulation of
triglycerides. The miR-30c targets PAI-1 (Plasminogen Activator
Inhibitor-1) and ALK2 (Activin-like kinase receptor 2), which are
downregulated by miR-30c in adipogenesis. The correlation of miR-
30c and PAI-1 was observed in WAT from obese mice, suggesting
an endocrine regulation role of these molecules during
obesity (113).
Concerning the insulin regulation by miRNAs, recent reports
suggest post-transcriptional mediated by IGF-1 (insulin-like growth
factor 1) and INSR (insulin receptor) activation (114), GLUT4
protein expression (115), pancreatic beta cells proliferation, and
differentiation (116, 117). The inhibition of miRNA-320 resulted in
increased insulin sensitivity, improved AKT phosphorylation and
GLUT4 expression (67, 118). The miRNA-93 expression was
inversely correlated with GLUT4 levels in adipose tissue from
non-obese insulin-resistant patients and its overexpression in
adipocytes downregulated GLUT4 expression (119).
miRNA-375 is one of the most abundant miRNAs in pancreatic
beta cells and overexpression of miR-375 can suppress glucose-
induced insulin secretion, and conversely, inhibition of endogenous
miR-375 function can enhance insulin secretion (110). This process
is mediated by myotrophin and PDK1 (Phosphoinositide-
dependent kinase-1), a key molecule in PI 3-kinase signaling
(120). The silencing of miR-375 in leptin-deficient diabetic mice
resulted in hyperglycemia, increased glucagon concentration, and
gluconeogenesis. In addition, miRNA-375 knockout mice presented
an altered pancreatic b cell mass, resulting in severe diabetes (69).
The miR-375 low levels in pancreatic beta cells are associated with
pancreatic cancer progression, metastasis, and angiogenesis (121).
Indeed, growing data have indicated a strong association of
metabolic syndrome or its components with cancer development
and cancer-related mortality (122–127). It is possible for the
association between metabolic syndrome and cancer to be
mediated by the dysfunctional adipose tissue, exacerbated
meta-inflammation, coexistence of obesity status, and insulin
resistance as the main factors. Importantly, adipose tissue
miRNAs could be the one of the key molecules orchestrating
this crosstalk linking metabolic syndrome and cancer.THE ROLE OF ADIPOSE TISSUE miRNAs
IN CANCER
Hanahan eWeinberg described the hallmarks of cancer, providing
new insights of carcinogenesis establishment, such as self-
sufficiency in growth signals, evading apoptosis, insensitivity toOctober 2020 | Volume 11 | Article 563816
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potential, tissue invasion and metastasis, immune response
evasion and metabolic reprogramming, genetic instability,
mutations, and tumor-promoting inflammation (128, 129). The
high plasticity of the adipose tissue and its inflammatory content
can directly regulate the tumor microenvironment, defining
cancer establishment and progression (12). The crosstalk
between adipocytes and other components of the adipose tissue,
such as immune cells, can be crucial to determine the cancer cells
fate (12). Adipose tissue–derived circulating miRNAs, considered
novel adipokines (130), can affect important signaling pathways,
directly impacting the carcinogenesis pillars.
Several studies reported a higher risk of cancer in patients with
obesity. There are at least 13 types of cancer which this correlation
is already described, such as esophagus (131), gastric (132), colon
and rectum (133), liver (134), prostate (135), ovary (136), kidney
(137), meningioma (138), thyroid (139), and multiple myeloma
(140). miRNA expression in adipose tissue from people with
obesity can play a crucial role in tumor progression, cancer
growth and metastasis. miRNAs mediate the crosstalk of
adipocytes and macrophages, modulating the inflammatory and
angiogenic microenvironment (141, 142). miRNAs are indeed
dysregulated in most, if not all, cancers (143). However, the
function of several miRNAs in cancer is very controversial in
the literature (144). Many reports are demonstrating unique
miRNAs acting both as miRNAs oncogenic (oncomiR) and
tumor-suppressive. Specific miRNAs can simultaneously trigger
anti-cancer effects by suppressing oncogenic mRNAs, and pro-
tumoral effects by suppressing tumor suppressive mRNAs. A
balance between these two signaling pathways will determine
whether a miRNA is an oncomiR or a tumor-suppressive
molecule (144).
The miRNA-377 is considered the master adipogenesis
regulator under stress stimulus in WAT (70). Studies reported
miRNA-377 targeting SIRT1 and reducing its expression in diet
obese mice, causing inflammation and insulin resistance in 3T3-L1
cells (70). SIRT1 exerts a role in tumor initiation, progression, and
angiogenic pathways (145), as depicted in murine hepatocellular
carcinoma (146), highlighting the potential antitumoral role of this
miRNA, through a SIRT pathway. SIRT1 is also correlated with
inflammation and insulin resistance, which contributes to the
development of a pro-tumoral environment, increasing the risk of
ROS (reactive oxygen species) production, thus leading to DNA
damage andmutations, genome instability, one of the hallmarks of
carcinogenesis (147).
The miRNA-34 family includes the miRNA-34a, miRNA-34b,
and miRNA-34c clusters, found in WAT. The tumoral suppressor
p53 is a direct transcriptional target of miR-34. The p53 is activated
under cellular stresses and promotes cell cycle arrest, senescence,
and apoptosis (148). Recent data also reports the role of p53 in
immune response, metabolism, and inflammation (149). The
miRNA-34 inhibits the proliferation of breast cancer cells
through a mechanism of SIRT1 and Bcl-2 downregulation (61),
and thus miR-34 seems to have an anti-tumor effect (150).
The cluster of miR-221 and miR-222 exerts a role in vascular
remodeling in atherogenic processes, inhibiting the angiogenicFrontiers in Endocrinology | www.frontiersin.org 8recruitment of endothelial cells, thus facilitating the atherogenic
calcification (63). These miRNAs are also related to human breast
cancer development, controlling the epithelial-to-mesenchymal
transition, downstream the oncogenic RAS-RAF-MEK pathway
(64). The miR-223 controls macrophage polarization preventing
mice from inflammation induced by diet and insulin resistance. The
anti-inflammatory mechanism described for miR-223 is the
suppression of classical proinflammatory M1 macrophages
response in adipose tissue (108).
The miR-125b controls mitochondria integrity and is related
to metabolic adaptations of monocytes, driving inflammation,
and apoptosis (65). The miR-100 was identified as an important
factor maintaining the M2 phenotype of tumor associated
adipose tissue macrophages. The miR-100 targets the mTOR
pathway and was also observed in some studies a higher
expression in tumor-associated macrophages isolated from
mouse breast tumor tissue. The therapeutic strategy of
combining miR-100 inhibition with cisplatin could suppress
mouse lung metastasis (151).
The miR-193b/126/26a are up-regulators of adiponectin
secretion in human white adipocytes, modifying the expression
of adiponectin regulators genes, such as the nuclear receptor-
interacting protein 1 and nuclear transcription factor Ya (152).
Adiponectin augments adipogenesis and prevent ectopic lipid
accumulation as liver steatosis, exerting a protective effect against
insulin resistance and cardiovascular diseases (153). Meta-
analysis studies demonstrated that low levels of adiponectin are
correlated to a higher risk of postmenopausal breast cancer (154)
and increased adiponectin serum levels confered a protective
effect on endometrial cancer (155).
Adipogenesis and immunological recruitment can alter the
tumor microenvironment. The miR-183 targets low-density
lipoprotein receptor-related protein in 3T3-L1 cells, promoting
differentiation and adipogenesis by interfering with the Wnt/b
catenin pathway (156) and tumor-derived TGF-b promotes
miR-183 expression, silencing NK cells, through a mechanism
mediated by DAP12 suppression. The DAP12 downregulation
facilitates the cancer establishment, avoiding NK cells to
recognize and eliminate the tumor cells, maintaining cancer
cells survival and spread, in a pathway dependent on miR-183,
suggesting a pro-tumoral role for this miRNA (157).
The miR-21 contributes with adipogenic differentiation of
human adipose tissue–derived mesenchymal stem cells, through
TGF-b signaling (71) and is also associated with cancer. The
overexpression of miR-21 was detected in pancreatic, colon,
breast, and glioblastoma tumors (158). Studies reported the
overexpression of miR-21 in colorectal cancer with advanced
metastasis stage. miR-21 is associated with anti-apoptotic effects,
promoting cellular proliferation by targeting tumor suppressors,
such as PTEN. Moreover, this event was inversely correlated with
miR-21 expression, as summarized in Figure 1 (72). Some
miRNAs act inhibiting tumor progression, leading to
oncogenes mRNA degradation or repression of the oncogenic
mRNA translation (159). The miR-15a/miR-16-1 cluster
interacts with Bcl-2 mRNA, resulting in leukemic cell
apoptosis (160).October 2020 | Volume 11 | Article 563816
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cells is associated with endothelial cell migration and
angiogenesis (161). Furthermore, Factor Inhibiting HIF-1a
(FIH), an anti-angiogenic gene is one of the targets of miR-31,
indicating a possible correlation between hypoxia, adipose tissue
dysfunction, and tumoral signaling pathways (161). Besides
angiogenic pathways facilitating the tumor cells spread, the
mitochondrial biogenesis and oxygen consumption can also be
associated with tumor growth (162). miRNAs can induce
mitochondrial metabolic alterations and a shift from oxidative
to glycolytic metabolism, by targeting components involved in
electron transport chain/oxidative phosphorylation (OXPHOS)
and in tricarboxylic acid cycle, thus contributing to Warburg
effect and cancer progression (163, 164). miR-126 can affect
mitochondrial function and mitochondrial metabolism in cancer
cells, leading to tumor suppression of cancer cells by inducing
tumor cells metabolic reprogramming (165). Obesity can reduce
the miR-126 expression (166), and this miRNA is often lost in
several types of cancer (167).
In both humans and mice, the miR-125b expression is higher
in WAT than in BAT, especially during obesity. It has been
shown that miR-125b-5p can play an important role in the
repression of brite adipocyte function by modulating oxygen
consumption and mitochondrial gene expression (66). The
higher expression of miR-125b was shown to be related to
prostate cancer risk, in a mechanism associated with
androgenic receptor stimulus, also promoting tumor growth by
modulating the cell cycle, apoptosis, and cell migration (168).
The role of miR-125b in stem-cells hematopoiesis, as well as the
activation and expression of this miRNA in human leukemia,
shows its function as an oncomiR (168). However, the role of
miR-125 in cancer is very controversial, since miR-125b can act
not only as an oncomiR in the vast majority of hematologic
malignancies, but also as a tumor suppressor in many solid
tumors (169, 170).
The miRNA-130 family, including miRNA-130a and
miRNA-130b, is deeply related to cancer progression (109,
171). It has been demonstrated the correlation of miR-130a
and miR-130b expression in preadipocytes isolated from
abdominal subcutaneous human adipose tissue and PPARg
repression, inhibiting adipogenesis (90). Likewise, PPAR g
activation could be protective against gastric cancer (172).
Increased levels of miR-130b were found in advanced tumor
stages (III–IV) of colorectal cancer patients (109). The
pharmacological inhibition of miR-130 family molecules by
seed-targeting with an 8-mer tiny locked nucleic acid (LNA)
inhibited bladder cancer cell growth, migration, and invasion by
repressing stress fiber formation (173). Overall, miRNA-130 is
highly expressed in patients with different types of cancer and is
correlated with severe tumors and poor cancer prognosis (174).
The miR-193b-365 cluster is defined as a brown fat-enriched
cluster, already depicted in lineage determination of brown
adipocytes, and brown adipocyte adipogenesis in mice studies
(105). The miR-193 has shown an anti-tumoral effect in breast
cancer, by decreasing cell proliferation and migration (175).
Besides, miR-193a-3p suppressed cancer gastric growth andFrontiers in Endocrinology | www.frontiersin.org 9motility (176). The miR-365 expression was downregulated in
glioblastoma (177) and inhibited cell proliferation of glioma and
malignant melanoma (177–179).
Studies reported the silencing of miR-145 associated with
increased liver inflammation in mice. Likewise, the lentivirus-
mediated miR-145 inhibited macrophage infiltration,
ameliorated glucose metabolism, and weight loss (180). This
target has been characterized as a tumor-suppressor miRNA,
impacting cell growth (59), leading to Myc proto-oncogene
downregulation (181). The miR-145 suppressed gastric cancer
cell proliferation through cell cycle arrest and apoptosis (182).
Another crucial miRNA related to BAT, is the miRNA-155.
The miRNA-155 acts in the adipogenic transcription factor
CCAAT/enhancer-binding protein b (84) and HIF-1a (73).
Studies demonstrated a higher expression of miR-155 in mice
intestinal tissue under hypoxia stimulus (73). Inflammation
upregulates miRNA-155 as seen in biopsies taken from
patients with obesity, and TNFa- treated adipocytes,
contributing to impair adipocytes function, as summarized in
Figure 1 (183). It was also described the correlation of miR-155
expression in lung cancer and hypoxia, which impacts tumor
microenvironment and cancer progression (74). The miR-155
can be involved in the chemotherapy resistance, and this could
be due to hypoxia and inflammation signaling pathways (184).
According to the miRNA target, the miRNA-based therapies
can follow two opposite directions, acting as tumor suppressor or
oncogenic molecules. The therapeutic strategy can be based on
miRNA antagonist molecules such as synthetic oligonucleotides
(antagomiRs), locked nucleic acids (LNA), a class of nucleic acid
analogs, capable of forming base pairs with complementary
nucleosides, demonstrating high affinity and resistant nucleases
degradation (185), silencing the oncogenic miRNA and finally
the miRNA mimetics in the tumor, restoring the protective
action of the miRNAs. AntagomiRs are oligonucleotides
developed to silence specific miRNA. Studies have reported
that intravenous administration of antagomiRs in mice
accomplished great results, with high specificity and low
toxicity (186).
The MRX34 drug, the liposomal formulation of a synthetic
miRNA-34a followed to phase 1 clinical trial. It was administered
intravenously in patients under advanced tumor stage and
refractory to standard chemotherapy. The drug strategy was
based on mimic miRNA therapy, to restore tumor suppressor
miRNAs levels, in solid cancers, such as liver and spleen (187).
However, due to serious adverse events, including immune
reactions, the clinical trials did not proceed to phase 2.
Although advances to clinical phase 3 have not been described,
new candidates, such as the drug RGLS5579, targeting miR-10b
in glioblastoma and inhibitors of miR-155 and miR-21 in the
treatment of hematological, breast and lung tumors have been
developed (188). In addition, LNA-anti-miR-21 for targeting
miR-21 expression to treat colon adenocarcinoma has been
investigated (189).
Remarkably, miRNAs are related to all hallmarks of cancer,
including uncontrolled cell proliferation and growth capacity,
cell death evasion, tumor-promoting inflammation signals,October 2020 | Volume 11 | Article 563816
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metastatic potential, energy metabolism reprogramming,
immune response evasion, and genomic instability. Overall,
several epigenetic and genetic modifications may occur in
cancer cells and lead to the gain of function of oncomiRs and
loss of function of tumor suppressor miRNAs. It is important to
note that several miRNAs can act both as oncomiR and tumor
suppressor molecules. Therapies based on miRNA must also
consider that cancer cells present an altered miRNAs expression,
and tumor phenotype can be changed by the modulation of the
miRNA expression. Therefore, a careful design and approach, is
essential to use miRNAs as very prominent therapeutic tool
against cancer.CONCLUSION
Obesity can often lead to metabolic impairment, triggering
inflammation, and contributing to disorders related to
adipogenesis and lipid metabolism. Adipose tissue–derived
miRNAs exert a crucial role in adipocyte differentiation,
adipogenesis, and hormone homeostasis being deeply related to
the establishment of metabolic syndrome, obesity and cancer.
miRNAs can act as oncogenes and tumor suppressor factors,Frontiers in Endocrinology | www.frontiersin.org 10depending on its expression and mRNA target, demonstrating a
defying way to pharmacological strategies, according to the tumor
microenvironment and the impaired signaling pathways. The ever
growing data showing the involvement of miRNAs in cancer
progression and invasion is supporting the arising use of miRNAs
for clinical assessment of cancer aggressiveness and tumor
biomarkers, as well as turning miRNAs in promising molecules
for therapeutic anti-cancer approaches. miRNAs can deeply
change important physiologic characteristics of white and BATs,
impacting browning of the WAT, modulating the inflammatory
response, and therefore influencing directly the obesity and
metabolic syndrome status, and thus cancer predisposition.
Moreover, adipose tissue is considered as the major source of
circulating miRNAs, acting both in paracrine and endocrine
signaling, modulating tumor microenvironment, affecting cancer
establishment and progression. Therefore, adipose tissue–derived
miRNAs may represent a promising therapeutic target against
metabolic syndrome, obesity, and cancer.AUTHOR CONTRIBUTIONS
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miR-34a directly targets tRNA i Met precursors and affects cellular
proliferation, cell cycle, and apoptosis. Proc Natl Acad Sci (2018)
115:7392–7. doi: 10.1073/pnas.1703029115
151. Wang W, Liu Y, Guo J, He H, Mi X, Chen C, et al. miR-100 maintains
phenotype of tumor-associated macrophages bytargeting mTOR to promote
tumor metastasis via Stat5a/IL-1ra pathway in mouse breastcancer.
Oncogenesis (2018) 7:1–17. doi: 10.1038/s41389-018-0106-y
152. Belarbi Y, Mejhert N, Lorente-Cebrián S, Dahlman I, Arner P, Rydén M,
et al. MicroRNA-193b controls adiponectin production in human white
adipose tissue. J Clin Endocrinol Metab (2015) 100:E1084–8. doi: 10.1210/
jc.2015-1530
153. Ouchi N, Walsh K. Adiponectin as an anti-inflammatory factor. Clin Chim
Acta (2009) 380:24–30. doi: 10.1016/j.cca.2007.01.026.Adiponectin
154. Ye J, Jia J, Dong S, Zhang C, Yu S, Li L, et al. Circulating adiponectin levels
and the risk of breast cancer: A meta-analysis. Eur J Cancer Prev (2014)
23:158–65. doi: 10.1097/CEJ.0b013e328364f293
155. Zheng Q, Wu H, Cao J. Circulating adiponectin and risk of endometrial
cancer. PloS One (2015) 10:1–11. doi: 10.1371/journal.pone.0129824
156. Chen C, Xiang H, Peng Y, Peng J, Jiang S. Mature miR-183, negatively
regulated by transcription factor GATA3, promotes 3T3-L1 adipogenesis
through inhibition of the canonical Wnt/b-catenin signaling pathway by
targeting LRP6. Cell Signal (2014) 26:1155–65. doi: 10.1016/
j.cellsig.2014.02.003
157. Donatelli SS, Zhou JM, Gilvary DL, Eksioglu EA, Chen X, Cress WD, et al.
TGF-b-inducible microRNA-183 silences tumor-associated natural killer
cells. Proc Natl Acad Sci USA (2014) 111:4203–8. doi: 10.1073/
pnas.1319269111
158. Feng YH, Tsao CJ. Emerging role of microRNA-21 in cancer (Review).
BioMed Rep (2016) 5:395–402. doi: 10.3892/br.2016.747
159. Ji W, Sun B, Su C. Targeting MicroRNAs in Cancer Gene Therapy. Genes
(Basel) (2017) 8:1–15. doi: 10.3390/genes8010021
160. Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M, et al.
miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci
USA (2005) 102:13944–9. doi: 10.1073/pnas.0506654102
161. Kang T, Jones TM, Naddell C, Bacanamwo M, Calvert JW, Thompson WE,
et al. Adipose-Derived Stem Cells Induce Angiogenesis via Microvesicle
Transport of miRNA-31. Stem Cells Transl Med (2016) 5:440–50. doi:
10.5966/sctm.2015-0177
162. Zong W, Rabinowitz JD, White E. Mitochondria and Cancer Wei-Xing. Mol
Cell (2016) 61:667–76. doi: 10.1016/j.molcel.2016.02.011.Mitochondria
163. Warburg O. On respiratory impairment in cancer cells.Sci (80- ) (1956)
124:269–70. doi: 10.1126/science.124.3215.267
164. Zheng J. Energy metabolism of cancer: Glycolysis versus oxidative
phosphorylation (Review). Oncol Lett (2012) 4:1151–7. doi: 10.3892/
ol.2012.928
165. Tomasetti M, Nocchi L, Staffolani S, Manzella N, Amati M, Goodwin J, et al.
MicroRNA-126 Suppresses Mesothelioma Malignancy by Targeting IRS1
and Interfering with the Mitochondrial Function. Antioxid Redox Signal
(2014) 21:2109–25. doi: 10.1089/ars.2013.5215Frontiers in Endocrinology | www.frontiersin.org 14166. Togliatto G, Dentelli P, Gili M, Gallo S, Deregibus C, Biglieri E, et al. Obesity
reduces the pro-angiogenic potential of adipose tissue stem cell-derived
extracellular vesicles (EVs) by impairing miR-126 content: impact on clinical
applications. Int J Obes (2016) 40:102–11. doi: 10.1038/ijo.2015.123
167. Duarte F, Palmeira C, Rolo A. The Role of microRNAs in Mitochondria:
Small Players Acting Wide. Genes (Basel) (2014) 5:865–86. doi: 10.3390/
genes5040865
168. Bousquet M, Harris MH, Zhou B, Lodish HF. MicroRNA miR-125b causes
leukemia. Proc Natl Acad Sci (2010) 107:21558–63. doi: 10.1073/pnas.1016611107
169. Shaham L, Binder V, Gefen N, Borkhardt A, Izraeli S. MiR-125 in normal
and malignant hematopoiesis. Leukemia (2012) 26:2011–8. doi: 10.1038/
leu.2012.90
170. Sun Y-M, Lin K-Y, Chen Y-Q. Diverse functions of miR-125 family in different
cell contexts. J Hematol Oncol (2013) 6:6. doi: 10.1186/1756-8722-6-6
171. Hirono T, Jingushi K, Nagata T, Sato M, Minami K, Aoki M, et al.
MicroRNA-130b functions as an oncomiRNA in non-small cell lung
cancer by targeting tissue inhibitor of metalloproteinase-2. Sci Rep (2019)
9:6956. doi: 10.1038/s41598-019-43355-8
172. Lu J, Imamura K, Nomura S, Mafune KI, Nakajima A, Kadowaki T, et al.
Chemopreventive effect of peroxisome proliferator-activated receptor g on
gastric carcinogenesis in mice. Cancer Res (2005) 65:4769–74. doi: 10.1158/
0008-5472.CAN-04-2293
173. Egawa H, Jingushi K, Hirono T, Hirose R, Nakatsuji Y, Ueda Y, et al.
Pharmacological regulation of bladder cancer by miR-130 familyseed-
targeting LNA. Integr Mol Med (2016) 3:1–7. doi: 10.15761/IMM.1000187
174. Peng Z, Duan F, Yin J, Feng Y, Yang Z, Shang J. Prognostic values of
microRNA-130 family expression in patients with cancer: a meta-analysis
and database test. J Transl Med (2019) 17:347. doi: 10.1186/s12967-019-
2093-y
175. Hulin JA, Tommasi S, Elliot D, Hu DG, Lewis BC, Mangoni AA. MiR-193b
regulates breast cancer cell migration and vasculogenic mimicry by targeting
dimethylarginine dimethylaminohydrolase. Sci Rep (2017) 7:1–15.
doi: 10.1038/s41598-017-14454-1
176. Chou N-H, Lo Y-H, Wang K-C, Kang C-H, Tsai C-Y, Tsai K-W. MiR-193a-
5p and -3p Play a Distinct Role in Gastric Cancer: miR-193a-3p Suppresses
Gastric Cancer Cell Growth by Targeting ETS1 and CCND1. Anticancer Res
(2018) 38:3309–18. doi: 10.21873/anticanres.12596
177. Yuan F, Liu J, Pang H, Tian Y, Yuan K, Li Y, et al. MicroRNA-365 suppressed
cell proliferation and migration viatargeting PAX6 in glioblastoma. Am J
Transl Res (2019)11:361–9. 1943-8141/AJTR0082995
178. Zhu Y, Zhao H, Rao M, Xu S. MicroRNA-365 inhibits proliferation,
migration and invasion of glioma by targeting PIK3R3. Oncol Rep (2017)
37:2185–92. doi: 10.3892/or.2017.5458
179. Bai J, Zhang Z, Li X, Liu H. MicroRNA-365 inhibits growth, invasion and
metastasis of malignant melanoma by targeting NRP1 expression. Cancer
Biomarkers (2015) 15:599–608. doi: 10.3233/CBM-150500
180. He M, Wu N, Leong MC, Zhang W, Ye Z, Li R, et al. miR-145 improves
metabolic inflammatory disease through multiple pathways. J Mol Cell Biol
(2020) 12:152–62. doi: 10.1093/jmcb/mjz015
181. Wang F, Xia J, Wang N, Zong H. miR-145 Inhibits Proliferation and
Invasion of Esophageal Squamous Cell Carcinoma in Part by Targeting c-
Myc. Oncol Res Treat (2013) 36:8–8. doi: 10.1159/000356978
182. Wang J, Sun Z, Yan S, Gao F. Effect of miR−145 on gastric cancer cells. Mol
Med Rep (2019) 5:3403–10. doi: 10.3892/mmr.2019.10015
183. Karkeni E, Astier J, Tourniaire F, El Abed M, Romier B, Gouranton E, et al.
Obesity-associated inflammation induces microRNA-155 expression in
adipocytes and adipose tissue: Outcome on adipocyte function. J Clin
Endocrinol Metab (2016) 101:1615–26. doi: 10.1210/jc.2015-3410
184. Bayraktar R, Van Roosbroeck K. miR-155 in cancer drug resistance and as
target for miRNA-based therapeutics. Cancer Metastasis Rev (2018) 37:33–
44. doi: 10.1007/s10555-017-9724-7
185. Chabot S, Orio J, Castanier R, Bellard E, Nielsen SJ, Golzio M, et al. LNA-
based oligonucleotide electrotransfer for miRNA inhibition.Mol Ther (2012)
20:1590–8. doi: 10.1038/mt.2012.95
186. Krützfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, Manoharan M,
et al. Silencing of microRNAs in vivo with “antagomirs.” Nature (2005)
438:685–9. doi: 10.1038/nature04303October 2020 | Volume 11 | Article 563816
Heyn et al. miRNAs in Obesity and Cancer187. Beg MS, Brenner AJ, Sachdev J, Borad M, Kang YK, Stoudemire J, et al. Phase
I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in
patients with advanced solid tumors. Invest New Drugs (2017) 35:180–8.
doi: 10.1007/s10637-016-0407-y
188. Hanna J, Hossain GS, Kocerha J. The potential for microRNA therapeutics and
clinicalresearch. Front Genet (2019) 10:1–6. doi: 10.3389/fgene.2019.00478
189. Nedaeinia R, SharifiM, Avan A, Kazemi M, Rafiee L, Ghayour-Mobarhan M,
et al. Locked nucleic acid anti-MIR-21 inhibits cell growth and invasive
behaviors of a colorectal adenocarcinoma cell line: LNA-anti-MIR as a novel
approach. Cancer Gene Ther (2016) 23:246–53. doi: 10.1038/cgt.2016.25Frontiers in Endocrinology | www.frontiersin.org 15Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
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